Gossamer Bio
Tracked across 3 events · 73 articles · First seen Feb 26, 2026 · Last active Apr 20, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
Gossamer Bio's stock price fell significantly after its Phase 3 PROSERA trial failed to meet its primary endpoint. This failure led to an investigation into potential securities fraud.
Feb 26, 2026 · 7 articles
Business
Gossamer Bio is facing a class action lawsuit for allegedly making false and misleading statements regarding its Phase 3 PROSERA study. The company's stock price plummeted by over 80% after the study failed to meet its primary endpoint, causing significant losses for investors.
Apr 01, 2026 · 59 articles
Business
Gossamer Bio is being sued in a class action for allegedly making false statements about its Phase 3 PROSERA study, which failed to meet its primary endpoint due to patient performance on placebo.
Apr 16, 2026 · 7 articles
100
Gossamer Bio disclosed failed Phase 3 PROSERA study resultsGossamer Bio Faces...
100
Gossamer Bio failed to meet primary endpoint in Phase 3 PROSERA studyGossamer Bio Faces...
95
Gossamer Bio stock price fell 80.3%Gossamer Bio Faces...
95
Gossamer Bio stock price fell by over 80%Gossamer Bio Faces...
85
Glancy Prongay & Rotter commenced investigation into federal securities law violations Gossamer BioGossamer Bio Faces...
85
Law Offices of Howard G. Smith initiated securities fraud lawsuit Gossamer BioGossamer Bio Faces...
85
Law Offices of Frank R. Cruz commenced investigation into federal securities law violations Gossamer BioGossamer Bio Faces...
80
Bronstein, Gewirtz & Grossman filed class action lawsuit Gossamer BioGossamer Bio Faces...
+ 6 more actions
View on Dashboard
NEWSDESK
Track Gossamer Bio live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard